About
Generics, Biologics Development, Small Molecules
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalGeneric DrugNJ, NY, PA
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
2,055
By Phase
PHASE2: 2PHASE1/PHASE2: 2
By Status
ACTIVE_NOT_RECRUITING: 3COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05816252Lead Sponsor
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
PHASE2Active, not recruiting
356 participants
Started: Apr 19, 2023 · Completed: Oct 30, 2026
NCT05642780Lead Sponsor
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
PHASE2Active, not recruiting
240 participants
Started: Jan 17, 2023 · Completed: Dec 31, 2027
NCT04152499Lead Sponsor
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
PHASE1/PHASE2Active, not recruiting
1,410 participants
Started: Feb 28, 2020 · Completed: Jul 16, 2026
NCT03602079Lead Sponsor
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
PHASE1/PHASE2Completed
49 participants
Started: Jul 16, 2018 · Completed: Jan 12, 2022
Locations (1)
Headquarters
Princeton, NJ, United States
Map
Loading map...